DLK1, a serum marker for hepatoblastoma in young infants

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 743-745

  Falix, Farah A ^a,b   Aronson, Daniel C ^a   Lamers, Wouter H ^b   Hiralall, Johan K ^b   Seppen, Jurgen ^b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

DLK1; Hepatoblastoma; Serum marker

Indexed keywords

ALPHA FETOPROTEIN; CELL MARKER; PROTEIN DELTA LIKE 1; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FETUS DEVELOPMENT; HEPATOBLASTOMA; HUMAN; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ALPHA-FETOPROTEINS; CHILD; CHILD, PRESCHOOL; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860298244     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24024     Document Type: Article

References (20)

1. Schnater JM, Kohler SE, Lamers WH, et al. Where do we stand with hepatoblastoma? A review. Cancer 2003; 98: 668-678.
2. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008; 13: 812-820.
3. von Schweinitz D. Neonatal liver tumours. Semin Neonatol 2003; 8: 403-410.
4. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28: 2584-2590.
5. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 2004; 40: 411-421.
6. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361: 1662-1670.
7. Otte JB, de Ville de GJ, Reding R. Liver transplantation for hepatoblastoma: Indications and contraindications in the modern era. Pediatr Transplant 2005; 9: 557-565.
8. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, et al. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74: 593-599.
9. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur J Cancer 2008; 44: 545-550.
10. von Schweinitz D, Gluer S, Mildenberger H. Liver tumors in neonates and very young infants: Diagnostic pitfalls and therapeutic problems. Eur J Pediatr Surg 1995; 5: 72-76.
11. Meyers RL. Tumors of the liver in children. Surg Oncol 2007; 16: 195-203.
12. Blohm ME, Vesterling-Horner D, Calaminus G, et al. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol 1998; 15: 135-142.
13. Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 1981; 15: 50-52.
14. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol 2000; 15: 119-129.
15. Floridon C, Jensen CH, Thorsen P, et al. Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation. Differentiation 2000; 66: 49-59.
16. Tanimizu N, Nishikawa M, Saito H, et al. Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci 2003; 116: 1775-1786.
17. Yevtodiyenko A, Schmidt JV. Dlk1 expression marks developing endothelium and sites of branching morphogenesis in the mouse embryo and placenta. Dev Dyn 2006; 235: 1115-1123.
18. Cairo S, Armengol C, De RA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-484.
19. Dezso K, Halasz J, Bisgaard HC, et al. Delta-like protein (DLK) is a novel immunohistochemical marker for human hepatoblastomas. Virchows Arch 2008; 452: 443-448.
20. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006; 44: 1012-1024.